Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANV/3TC/TDF switch study in older treatment-experienced people with HIV and dyslipidemia in Guangxi
ChiCTR2400084317Phase 4Not yet recruiting
- Sponsor
- Nanning Fourth People's Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ainuovirine, lamivudine and tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV), sponsored by Nanning Fourth People's Hospital. Primary endpoint: Change in four-part lipid profile. Planned start May 2024; status: not yet recruiting.
02
Drugs
ainuovirinelamivudinetenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2400084317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084317.